Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRT7732 in SMARCA4-mutated advanced solid tumors
NCT06560645Phase 1Terminated
- Sponsor
- Prelude Therapeutics
- Start
- Nov 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of PRT7732 in non-small cell lung carcinoma (NSCLC), esophageal adenocarcinoma (EAC), Esophageal Squamous Cell Carcinoma (ESCC) and 4 more, sponsored by Prelude Therapeutics. Primary endpoints: Dose Limiting Toxicity at 21 days, Safety and Tolerability as Measured by Incidence of DLTs at 2 years and 4 more. Started Nov 2024; status: terminated.
02
Drugs
PRT7732
03
Conditions
non-small cell lung carcinoma (NSCLC)esophageal adenocarcinoma (EAC)Esophageal Squamous Cell Carcinoma (ESCC)gastric adenocarcinomagastric squamous cell carcinoma (GSCC)
Beyond the preview
Go deeper on NCT06560645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06560645.